Ivosidenib, an oral, selective mutant IDH1 inhibitor, has shown promising results in a Phase III trial, significantly improving progression-free survival (PFS) and OS in advanced CCA (Abou-Alfa et al., 2020a). This evidence concerns the gene IDH1 and cholangiocarcinoma.